Upload Avatar (500 x 500)
Xiaojing Zhang
Medical School
Wuhan University
Hubei
Language: Chinese, English
Liver Injury
Drug Development
Chronic Liver Disease
Acute Liver Disease
Non-Alcoholic Fatty Liver Disease
Liver Metabolism
Ischemia-Reperfusion
Multi-Organ Damage
Pathological Mechanisms
Therapeutic Targets
Areas of Focus
- Mechanisms of acute and chronic liver injury and drug development
- Pathological mechanisms of non-alcoholic fatty liver disease and related liver metabolic diseases and drug development
- Core drivers of multi-organ damage caused by ischemia-reperfusion and drug development
Work Experience
- 2016-2019 Assistant Researcher, Central Laboratory, Wuhan University People's Hospital
- 2020-2021 Distinguished Researcher, Animal Experiment Center, Wuhan University
- 2021-present Distinguished Researcher, School of Basic Medical Sciences, Wuhan University
Academic Background & Achievements
- 2005-2009 Bachelor in Pharmaceutical Engineering, Beijing University of Chinese Medicine
- 2009-2012 Master in Natural Medicinal Chemistry, Peking University Health Science Center
- 2012-2016 PhD in Biopharmaceuticals, University of Macau
Publications
- The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19, Zhang XJ, et al., 2021
- Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis, Zhang XJ, et al., 2020
- Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis, Zhang XJ, et al., 2020
- Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, Zhang XJ, et al., 2020
- Integrated Omics Reveals Tollip as a Regulator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice, Zhang XJ, et al., 2019
- In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19, Zhang XJ, et al., 2020
- An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Zhang XJ, et al., 2018
- Time to step-up the fight against NAFLD, Zhang XJ, et al., 2018
- Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Zhang XJ, et al., 2017
- The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis, Zhang XJ, et al., 2017
